23277-43-2Cl.Oc1ccc2c3c1O[C@H]1[C@@H](O)CC[C@@]4(O)[C@@H](C2)N(CC2CCC2)CC[C@]314YZLZPSJXMWGIFH-BCXQGASESA-NNalbuphine Hydrochloride is the hydrochloride salt form of nalbuphine, a synthetic phenanthrene opioid with opiate agonist and antagonist effects, used to treat moderate to severe pain and provide preoperative and postoperative analgesia and sedation. Nalbuphine hydrochloride binds to kappa-, mu- and delta-opioid receptors but not to sigma-opioid receptors. This opioid exerts its analgesic actions primarily through kappa-opioid-receptor agonism and partially through mu-opioid receptor agonism.
23277-43-2DTXSID20177844CHEMBL1201132FDA approved drugs -> Active ingredient
FDA approved drugs -> Active ingredient
Sicherheitsangaben dienen nur zur Orientierung und ersetzen weder das Sicherheitsdatenblatt (SDB) des Lieferanten noch geltende Vorschriften oder eine fachliche Bewertung.
Danger
H300 (63.9%): Fatal if swallowed [Danger Acute toxicity, oral]
P233, P260, P261, P262, P264, P270, P271, P272, P280, P284, P301+P316, P301+P317, P302+P352, P304+P340, P316, P317, P320, P321, P330, P333+P317, P342+P316, P361+P364, P362+P364, P403, P403+P233, P405, and P501 (click each P-code to see the statement)
Aggregated GHS information provided per 61 reports by companies from 6 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.
Drug Induced Liver Injury Rank (DILIrank 2.0)
Nalbuphine hydrochloride
vNo-DILI-concern
0
No match
DOI:10.1016/j.drudis.2016.02.015
NALBUPHINE HCI
Competitive Opioid Antagonists [MoA]; Partial Opioid Agonists [MoA]; Opioid Agonist/Antagonist [EPC]
NALBUPHINE HYDROCHLORIDE
Opioid Agonist/Antagonist [EPC]; Partial Opioid Agonists [MoA]; Competitive Opioid Antagonists [MoA]